Adverse effects of GLP-1 receptor agonists (revision 2)
Old revision·21:35, 2 Jul 2024·Chromatokid
This is an old revision of this page, as it stood at 21:35, 2 Jul 2024, saved by Chromatokid with the summary expand §Body composition and other effects. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| Adverse effects of GLP-1 receptor agonists | |
|---|---|
| Most common | Nausea, vomiting, diarrhoea, constipation |
| Timing | Concentrated during escalation |
| Commonest reason for discontinuation | Gastrointestinal intolerance |
| Topic infobox · conventions | |
The adverse effects of GLP-1 receptor agonists are dominated by gastrointestinal events. Nausea, vomiting, diarrhoea and constipation are reported by between a fifth and a half of participants in trials depending on agent and dose, are most frequent during escalation, and diminish with time at a stable dose.[1]
Their mechanism is receptor-level rather than route-level: the same effects occur with an orally administered small-molecule agonist, which argues against a local gastrointestinal irritation explanation. Delayed gastric emptying and area postrema signalling are the proposed contributors.[1]